This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (71)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Clinical Trial

Ronald B. Turner, MD; Margaret T. Wecker, PhD; Gerhardt Pohl, PhD; Theodore J. Witek, DrPH; Eugene McNally, PhD; Roger St. George, MS; Birgit Winther, MD; Frederick G. Hayden, MD

JAMA. 1999;281:1797-1804.

Context  Attachment of most rhinovirus subtypes to cells depends on a cellular receptor, the intercellular adhesion molecule 1 (ICAM-1). A recombinant soluble ICAM-1 (tremacamra, formerly BIRR 4) has shown possible efficacy in early studies.

Objective  To determine the efficacy and safety of intranasal administration of tremacamra in experimental rhinovirus colds in humans.

Design  Four randomized, double-blind, placebo-controlled trials conducted in January to March 1996.

Setting and Subjects  Volunteers between the ages of 18 and 60 years who had an antibody titer of 1:4 or less to the challenge virus. Subjects were isolated in a hotel room during study days 0 to 8; symptoms were recorded through day 14. A total of 198 subjects were randomized, of whom 196 received drug or placebo and were included in the safety analysis. A total of 177 subjects were included in the efficacy analysis.

Interventions  Tremacamra or placebo was given beginning 7 hours before inoculation with rhinovirus type 39 (preinoculation studies) or 12 hours after (postinoculation studies). Tremacamra as an inhaled solution or as a powder (each given preinoculation and postinoculation for a total of 4 studies) and placebo were given in 6 doses at 3-hour intervals daily during days 1 through 7. Recipients of active treatment received 367 µg of tremacamra per nostril per dose for a total of 4.4 mg/d.

Main Outcome Measures  Effect of tremacamra on infection, as determined by virus isolation and seroconversion, and on illness, as determined by symptom scores, clinical colds, and nasal mucus weights. Treatment-by-study interaction was not significant, so results were pooled for the main analysis.

Results  A total of 88 (92%) of the 96 subjects in the placebo groups and 69 (85%) of the 81 subjects in the active treatment groups were infected (P=.19). For placebo vs tremacamra, respectively, the total symptom score (± 95% confidence interval [CI]) was 17.6 (± 2.7) vs 9.6 (± 2.9), the proportion of clinical colds was 64/96 (67% ± 9%) vs 36/81 (44% ± 11%), and the nasal mucus weight was 32.9 (± 8.8) g vs 14.5 (± 9.4) g (P<.001 for all comparisons). Tremacamra was not associated with adverse effects or evidence of absorption through the nasal mucosa and did not interfere with development of neutralizing antibody.

Conclusion  Tremacamra reduced the severity of experimental rhinovirus colds. Whether tremacamra will be useful clinically will require further study.

Author Affiliations: Departments of Pediatrics and Laboratory Medicine, Medical University of South Carolina, Charleston (Dr Turner); Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Conn (Drs Wecker, Pohl, Witek, and McNally, and Mr St. George); and Departments of Otolaryngology (Dr Winther) and Internal Medicine and Pathology (Dr Hayden), University of Virginia Health Sciences Center, Charlottesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Closer to a Cure for the Common Cold?

JAMA. ;281():1844-1845.
FULL TEXT  

May 19, 1999
JAMA. ;281():1863-1864.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances
Nichols et al.
Clin. Microbiol. Rev. 2008;21:274-290.
ABSTRACT | FULL TEXT  

Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Martinez
Proc Am Thorac Soc 2007;4:647-658.
ABSTRACT | FULL TEXT  

Relations among questionnaire and laboratory measures of rhinovirus infection
Barrett et al.
Eur Respir J 2006;28:358-361.
ABSTRACT | FULL TEXT  

Shedding of soluble ICAM-1 into the alveolar space in murine models of acute lung injury
Mendez et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2006;290:L962-L970.
ABSTRACT | FULL TEXT  

Inhibition of Polyprotein Processing and RNA Replication of Human Rhinovirus by Pyrrolidine Dithiocarbamate Involves Metal Ions
Krenn et al.
J. Virol. 2005;79:13892-13899.
ABSTRACT | FULL TEXT  

An Evaluation of Echinacea angustifolia in Experimental Rhinovirus Infections
Turner et al.
NEJM 2005;353:341-348.
ABSTRACT | FULL TEXT  

Increased Arterial Carboxyhemoglobin Concentrations in Chronic Obstructive Pulmonary Disease
Yasuda et al.
Am. J. Respir. Crit. Care Med. 2005;171:1246-1251.
ABSTRACT | FULL TEXT  

The case for rhinoviruses in the pathogenesis of multiple sclerosis
Kriesel and Sibley
Mult Scler 2005;11:1-4.
 

Using Benefit Harm Tradeoffs to Estimate Sufficiently Important Difference: The Case of the Common Cold
Barrett et al.
Med Decis Making 2005;25:47-55.
ABSTRACT  

Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers
Hayden et al.
Antimicrob. Agents Chemother. 2003;47:3907-3916.
ABSTRACT | FULL TEXT  

Diagnosis and Treatment of Rhinovirus Respiratory Infections
Anzueto and Niederman
Chest 2003;123:1664-1672.
ABSTRACT | FULL TEXT  

Human Rhinovirus Selectively Modulates Membranous and Soluble Forms of Its Intercellular Adhesion Molecule-1 (ICAM-1) Receptor to Promote Epithelial Cell Infectivity
Whiteman et al.
J. Biol. Chem. 2003;278:11954-11961.
ABSTRACT | FULL TEXT  

Respiratory Consequences of Rhinovirus Infection
Greenberg
Arch Intern Med 2003;163:278-284.
ABSTRACT | FULL TEXT  

Pneumonia due to viral and atypical organisms and their sequelae: Childhood respiratory infections
Smyth
Br Med Bull 2002;61:247-262.
ABSTRACT | FULL TEXT  

Virus-Induced Asthma Attacks
Jacoby
JAMA 2002;287:755-761.
ABSTRACT | FULL TEXT  

Expression of ICAM-1 in Nasal Epithelium and Levels of Soluble ICAM-1 in Nasal Lavage Fluid During Human Experimental Rhinovirus Infection
Winther et al.
Arch Otolaryngol Head Neck Surg 2002;128:131-136.
ABSTRACT | FULL TEXT  

Erythromycin and Common Cold in COPD
Suzuki et al.
Chest 2001;120:730-733.
ABSTRACT | FULL TEXT  

New treatments for viral respiratory tract infections--opportunities and problems
Snell
J Antimicrob Chemother 2001;47:251-259.
FULL TEXT  

Relationship of Upper and Lower Airway Cytokines to Outcome of Experimental Rhinovirus Infection
GERN et al.
Am. J. Respir. Crit. Care Med. 2000;162:2226-2231.
ABSTRACT | FULL TEXT  

A Family Physician's Perspective on Picornavirus Infections in Primary Care
Temte
Arch Fam Med 2000;9:921-922.
FULL TEXT  

Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate: A Randomized, Double-Blind, Placebo-Controlled Trial
Prasad et al.
ANN INTERN MED 2000;133:245-252.
ABSTRACT | FULL TEXT  

Promising New Agent for Rhinovirus Infections
JWatch Infect. Diseases 1999;1999:4-4.
FULL TEXT  

High-Tech Treatment for the Common Cold
Journal Watch Dermatology 1999;1999:15-15.
FULL TEXT  

High-Tech Treatment for the Common Cold
JWatch General 1999;1999:4-4.
FULL TEXT  

Closer to a Cure for the Common Cold?
McIntosh
JAMA 1999;281:1844-1845.
FULL TEXT